Eli Lilly Stock: A Buy on the Path to $1,000?

Eli Lilly (LLY) recently reported another strong quarter, driven by its leadership in the booming GLP-1 drug market. Key products Mounjaro and Zepbound continue to fuel impressive growth, with the company's revenue surging nearly 60% year-over-year.

Despite these fantastic results, the stock has pulled back from its all-time highs above $1,100 earlier this year. As of this analysis, it was trading around $960, creating a disconnect between its operational performance and its recent share price movement.

The analyst community remains overwhelmingly bullish. The consensus price target sits around $1,215, implying a potential 26% upside from current levels. Out of 30 analysts covering the stock, 25 rate it as a buy.

Even analysts who have recently trimmed their targets still see the stock climbing well past the $1,000 mark in the near term, highlighting sustained confidence in the company's trajectory.

This matters because the recent price dip has made Eli Lilly's valuation more attractive. While the stock isn't cheap, its price-to-earnings ratio has come down significantly as earnings have skyrocketed, offering a better entry point for a premier growth company.

The core of the investment thesis is the transformative growth story. Lilly's sales have more than doubled from $28.5 billion in 2022 to $65.2 billion in 2025, while profits have tripled to $20.6 billion. This demonstrates the massive commercial success of its new drug portfolio.

For long-term investors, the potential extends far beyond the $1,000 psychological barrier. The GLP-1 market for diabetes and obesity is still in its early innings, and Lilly is a clear leader with a robust pipeline, suggesting growth can continue for years.

The key risk is execution and competition. The company must continue to meet overwhelming demand for its drugs and fend off rivals like Novo Nordisk. However, its current momentum and financial firepower give it a strong competitive edge.